drugset / Trial / NCT06963281
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
Phase 1
Recruiting
285 enrolled
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Fortvita Biologics (USA)Inc. · collab
NaSequentialOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.
Timeline
- Start
- 2025-04-29
- Primary completion
- 2027-12-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI3020 | Monoclonal antibody | — | — |